Back

Sex differences in outcomes among patients undergoing transcatheter atrial septal defect closure: Do they benefit equally?

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: All about septal defects Intervention ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Lore Schrutka

Medical University of Vienna, Vienna (Austria)

8 More presentations in this session

Presentation thumbnail
Transcatheter closure of atrial septal defect (ASD) in adult and paediatric population without transoesophageal echocardiography/general anaesthesia
Associate Professor P. Barwad (Chandigarh, IN)
Abstract Slides Video
Presentation thumbnail
The incidence of atrial fibrillation in patients with interatrial shunt:is it reduced after surgical or transcatheter closure of the shunt?
Doctor A. Karagianni (Gothenburg, SE)
Abstract Slides Video
Presentation thumbnail
Outcome of pregnancy in women with unrepaired atrial septal defect - study of a single tertiary centre
Doctor D. Kecskemeti (Budapest, HU)
Abstract Slides Video
Presentation thumbnail
Transcranial doppler to detect high-risk PFO and predict decompression illness in divers
Doctor H. Lee (Bucheon, KR)
Abstract Slides Video
Presentation thumbnail
4-year follow-up results of percutaneous closure of atrial septal defect with the total biodegradable poly-L-lactic acid device: date from a prospective, single-center trial
Doctor Y. Li (Guangzhou, CN)
Abstract Slides Video

Access the full session

Session thumbnail
All about septal defects

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Sex differences in outcomes of percutaneous left atrial appendage closure
thumbnail
Congress Presentation
Sex difference in characteristics and outcomes for transcatheter aortic valve implantation: a nationwide japanese study
thumbnail
Congress Presentation
Outcomes of CT- or CMR-guided TAVR according to sex: a secondary analysis of the randomized TAVR-CMR trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources